Literature DB >> 24735980

Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain.

Marzia Perluigi1, Gilda Pupo1, Antonella Tramutola1, Chiara Cini1, Raffaella Coccia1, Eugenio Barone1, Elizabeth Head2, D Allan Butterfield3, Fabio Di Domenico4.   

Abstract

Down syndrome (DS) is the most frequent genetic cause of intellectual disability characterized by the presence of three copies of chromosome 21 (Chr21). Individuals with DS have sufficient neuropathology for a diagnosis of Alzheimer's disease (AD) after the age of 40years. The aim of our study is to gain new insights in the molecular mechanisms impaired in DS subjects that eventually lead to the development of dementia. We evaluate the PI3K/Akt/mTOR axis in the frontal cortex from DS cases (under the age of 40years) and DS with AD neuropathology compared with age-matched controls (Young and Old). The PI3K/Akt/mTOR axis may control several key pathways involved in AD that, if aberrantly regulated, affect amyloid beta (Aβ) deposition and tau phosphorylation. Our results show a hyperactivation of PI3K/Akt/mTOR axis in individuals with DS, with and without AD pathology, in comparison with respective controls. The PI3K/Akt/mTOR deregulation results in decreased autophagy, inhibition of IRS1 and GSK3β activity. Moreover, our data suggest that aberrant activation of the PI3K/Akt/mTOR axis acts in parallel to RCAN1 in phosphorylating tau, in DS and DS/AD. In conclusion, this study provides insights into the neuropathological mechanisms that may be engaged during the development of AD in DS. We suggest that deregulation of this signaling cascade is already evident in young DS cases and persist in the presence of AD pathology. The impairment of the PI3K/Akt/mTOR axis in DS population might represent a key-contributing factor to the neurodegenerative process that culminates in Alzheimer-like dementia.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Akt; Autophagy; Insulin signaling; PI3K; Trisomy 21; mTOR

Mesh:

Substances:

Year:  2014        PMID: 24735980      PMCID: PMC4062876          DOI: 10.1016/j.bbadis.2014.04.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  76 in total

Review 1.  Genetic and host factors for dementia in Down's syndrome.

Authors:  Nicole Schupf; Gertrude H Sergievsky
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

Review 2.  The brain in Down syndrome (TRISOMY 21).

Authors:  Gert Lubec; Ephrem Engidawork
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

3.  Amyloid beta oligomers induce impairment of neuronal insulin receptors.

Authors:  Wei-Qin Zhao; Fernanda G De Felice; Sara Fernandez; Hui Chen; Mary P Lambert; Michael J Quon; Grant A Krafft; William L Klein
Journal:  FASEB J       Date:  2007-08-24       Impact factor: 5.191

Review 4.  Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease.

Authors:  Renato X Santos; Sónia C Correia; Susana Cardoso; Cristina Carvalho; Maria S Santos; Paula I Moreira
Journal:  J Neurochem       Date:  2011-05-03       Impact factor: 5.372

Review 5.  Regulating insulin signaling and beta-cell function through IRS proteins.

Authors:  Morris F White
Journal:  Can J Physiol Pharmacol       Date:  2006-07       Impact factor: 2.273

6.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

Review 7.  Beta-amyloid, oxidative stress and down syndrome.

Authors:  Ira T Lott; Elizabeth Head; Eric Doran; Jorge Busciglio
Journal:  Curr Alzheimer Res       Date:  2006-12       Impact factor: 3.498

Review 8.  Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2012-10-05       Impact factor: 7.376

Review 9.  Autophagy, amyloidogenesis and Alzheimer disease.

Authors:  Ralph A Nixon
Journal:  J Cell Sci       Date:  2007-12-01       Impact factor: 5.285

10.  Altered regulation of tau phosphorylation in a mouse model of down syndrome aging.

Authors:  Olivia Sheppard; Florian Plattner; Anna Rubin; Amy Slender; Jacqueline M Linehan; Sebastian Brandner; Victor L J Tybulewicz; Elizabeth M C Fisher; Frances K Wiseman
Journal:  Neurobiol Aging       Date:  2011-08-16       Impact factor: 4.673

View more
  50 in total

1.  Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Cesare Mancuso; Eugenio Barone; Francesca Paolini; Andrea Arena; Carla Blarzino; Frederick A Schmitt; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99).

Authors:  Ying Jiang; Yutaka Sato; Eunju Im; Martin Berg; Matteo Bordi; Sandipkumar Darji; Asok Kumar; Panaiyur S Mohan; Urmi Bandyopadhyay; Antonio Diaz; Ana Maria Cuervo; Ralph A Nixon
Journal:  J Neurosci       Date:  2019-05-01       Impact factor: 6.167

Review 3.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

Review 4.  Exercise for the diabetic brain: how physical training may help prevent dementia and Alzheimer's disease in T2DM patients.

Authors:  Sebastian Bertram; Klara Brixius; Christian Brinkmann
Journal:  Endocrine       Date:  2016-05-09       Impact factor: 3.633

5.  L-3-n-Butylphthalide Activates Akt/mTOR Signaling, Inhibits Neuronal Apoptosis and Autophagy and Improves Cognitive Impairment in Mice with Repeated Cerebral Ischemia-Reperfusion Injury.

Authors:  Jing Xu; Yaping Huai; Nan Meng; Yanhong Dong; Zhijuan Liu; Qianqian Qi; Ming Hu; Mingyue Fan; Wei Jin; Peiyuan Lv
Journal:  Neurochem Res       Date:  2017-06-15       Impact factor: 3.996

6.  Down Syndrome iPSC-Derived Astrocytes Impair Neuronal Synaptogenesis and the mTOR Pathway In Vitro.

Authors:  Bruno H S Araujo; Carolini Kaid; Janaina S De Souza; Sérgio Gomes da Silva; Ernesto Goulart; Luiz C J Caires; Camila M Musso; Laila B Torres; Adriano Ferrasa; Roberto Herai; Mayana Zatz; Oswaldo K Okamoto; Esper A Cavalheiro
Journal:  Mol Neurobiol       Date:  2017-11-11       Impact factor: 5.590

Review 7.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

Review 8.  Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives.

Authors:  Chiara Lanzillotta; Fabio Di Domenico; Marzia Perluigi; D Allan Butterfield
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

9.  Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.

Authors:  Azhar R Hussain; Maha Al-Romaizan; Maqbool Ahmed; Saravanan Thangavel; Fouad Al-Dayel; Shaham Beg; Shahab Uddin; Abdul K Siraj; Khawla S Al-Kuraya
Journal:  Mol Med       Date:  2015-05-26       Impact factor: 6.354

Review 10.  Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology.

Authors:  Antonella Tramutola; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Alessandra Giorgi; Laura di Francesco; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Antioxid Redox Signal       Date:  2016-10-26       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.